Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings-Reference-Cited by-同舟云学术

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

Published:2019-03-22 Issue: Volume:10 Page:
ISSN:1664-2295
Container-title:Frontiers in Neurology
language:
Short-container-title:Front. Neurol.

Author:

Barclay Krista,Carruthers Robert,Traboulsee Anthony,Bass Ann D.,LaGanke Christopher,Bertolotto Antonio,Boster Aaron,Celius Elisabeth G.,Seze Jérôme de,Cruz Dionisio Dela,Habek Mario,Lee Jong-Mi,Limmroth Volker,Meuth Sven G.,Oreja-Guevara Celia,Pagnotta Patricia,Vos Cindy,Ziemssen Tjalf,Baker Darren P.,Wijmeersch Bart Van

Funder

Sanofi

Publisher

Frontiers Media SA

Subject

Neurology (clinical),Neurology

Reference63 articles.

1. The changing demographic pattern of multiple sclerosis epidemiology;Koch-Henriksen;Lancet Neurol.,2010

2. Effect of relapses on development of residual deficit in multiple sclerosis;Lublin;Neurology.,2003

3. Multiple sclerosis;Compston;Lancet.,2002

4. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis;Friese;Nat Rev Neurol.,2014

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy–A case series;Multiple Sclerosis and Related Disorders;2024-10

2. ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation;PharmacoEconomics - Open;2024-07-11

3. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis;Expert Review of Neurotherapeutics;2023-05-04

4. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2023-01

5. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study;Therapeutic Advances in Neurological Disorders;2023-01